Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

15 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.2%

5 terminated out of 81 trials

Success Rate

90.4%

+3.9% vs benchmark

Late-Stage Pipeline

10%

8 trials in Phase 3/4

Results Transparency

32%

15 of 47 completed with results

Key Signals

15 with results90% success

Data Visualizations

Phase Distribution

65Total

Not Applicable (10)

Early P 1 (1)

P 1 (21)

P 2 (25)

P 3 (7)

P 4 (1)

Trial Status

Completed47

Recruiting18

Active Not Recruiting6

Terminated5

Unknown4

Withdrawn1

Trial Success Rate

90.4%

Benchmark: 86.5%

Based on 47 completed trials

Clinical Trials (81)

Showing 20 of 20 trials

NCT06456346Phase 3RecruitingPrimary

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT01384513Phase 2Completed

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

NCT03289910Phase 2Active Not Recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT06661915Phase 2Recruiting

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

NCT06063486Phase 2Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

NCT05198960Phase 3Recruiting

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT04282187Phase 2Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

NCT06079879Phase 3RecruitingPrimary

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT03862157Phase 1Active Not Recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT05123365Phase 1Recruiting

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

NCT04942080Not ApplicableRecruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

NCT01199562Active Not Recruiting

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

NCT04644211Phase 2RecruitingPrimary

Ruxolitinib in Thrombocythemia and Polycythemia Vera

NCT04262141Phase 2Active Not RecruitingPrimary

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

NCT06361641Not ApplicableRecruiting

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

NCT06552429Phase 2RecruitingPrimary

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

NCT05031897Phase 2Recruiting

Two Step Haplo With Radiation Conditioning

NCT03878199Phase 1CompletedPrimary

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms